These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19099325)

  • 1. Trekkers' awareness of acute mountain sickness and acetazolamide.
    Subedi D; Marahatta R; Sharma S; Bajracharya R; Hillenbrand P; Soon Y
    Wilderness Environ Med; 2008; 19(4):321-2. PubMed ID: 19099325
    [No Abstract]   [Full Text] [Related]  

  • 2. Trekker behavior as one indicator of AMS knowledge.
    Dunin-Bell O; Chin M; Boyle S
    Wilderness Environ Med; 2010 Mar; 21(1):83-5; author reply 85-6. PubMed ID: 20591364
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute mountain sickness prophylaxis: knowledge, attitudes, & behaviours in the Everest region of Nepal.
    Kilner T; Mukerji S
    Travel Med Infect Dis; 2010 Nov; 8(6):395-400. PubMed ID: 21112541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding of Altitude Illness and Use of Pharmacotherapy Among Trekkers and Porters in the Annapurna Region of Nepal.
    Havryliuk T; Acharya B; Caruso E; Cushing T
    High Alt Med Biol; 2015 Sep; 16(3):236-43. PubMed ID: 26244262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute mountain sickness impact among travelers to Cusco, Peru.
    Salazar H; Swanson J; Mozo K; White AC; Cabada MM
    J Travel Med; 2012 Jul; 19(4):220-5. PubMed ID: 22776382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up.
    Gaillard S; Dellasanta P; Loutan L; Kayser B
    High Alt Med Biol; 2004; 5(4):410-9. PubMed ID: 15671630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Awareness of altitude sickness among visitors to a North American ski resort.
    Hatzenbuehler J; Glazer J; Kuhn C
    Wilderness Environ Med; 2009; 20(3):257-60. PubMed ID: 19737036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of summiting success and acute mountain sickness on Mt Kilimanjaro (5895 m).
    Davies AJ; Kalson NS; Stokes S; Earl MD; Whitehead AG; Frost H; Tyrell-Marsh I; Naylor J
    Wilderness Environ Med; 2009; 20(4):311-7. PubMed ID: 20030437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence of acute mountain sickness at intermediate altitude in the Austrian alps].
    Röggla G; Röggla M; Hirschl MM; Wagner A; Laggner AN
    Wien Klin Wochenschr Suppl; 1992; 194():7-10. PubMed ID: 1288024
    [No Abstract]   [Full Text] [Related]  

  • 10. Age is no barrier to success at very high altitudes.
    Stokes S; Kalson NS; Earl M; Whitehead AG; Tyrrell-Marsh I; Frost H; Davies A
    Age Ageing; 2010 Mar; 39(2):262-5. PubMed ID: 20068217
    [No Abstract]   [Full Text] [Related]  

  • 11. Can knowledge protect against acute mountain sickness?
    Vardy J; Vardy J; Judge K
    J Public Health (Oxf); 2005 Dec; 27(4):366-70. PubMed ID: 16234261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetazolamide and high altitude diseases.
    Bradwell AR; Wright AD; Winterborn M; Imray C
    Int J Sports Med; 1992 Oct; 13 Suppl 1():S63-4. PubMed ID: 1483796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methazolamide and acetazolamide in acute mountain sickness.
    Wright AD; Bradwell AR; Fletcher RF
    Aviat Space Environ Med; 1983 Jul; 54(7):619-21. PubMed ID: 6349608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of changing trekker demographics on travel health in the Annapurna region.
    Kc B; Heydon S; Norris P
    Public Health; 2019 Mar; 168():157-163. PubMed ID: 30415826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile.
    Moraga FA; Flores A; Serra J; Esnaola C; Barriento C
    Wilderness Environ Med; 2007; 18(4):251-7. PubMed ID: 18076292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial.
    Chow T; Browne V; Heileson HL; Wallace D; Anholm J; Green SM
    Arch Intern Med; 2005 Feb; 165(3):296-301. PubMed ID: 15710792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serious and sometimes fatal consequences of high-altitude pulmonary oedema].
    Berendsen RR; Willems JH; Bosch FH; Hulsebosch R; Kayser B
    Ned Tijdschr Geneeskd; 2008 Dec; 152(51-52):2758-62. PubMed ID: 19177913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetazolamide for acute mountain sickness.
    FDA Drug Bull; 1983 Nov; 13(3):27. PubMed ID: 6653952
    [No Abstract]   [Full Text] [Related]  

  • 19. Everest or bust: a cross sectional, epidemiological study of acute mountain sickness at 4243 meters in the Himalayas.
    Basnyat B; Lemaster J; Litch JA
    Aviat Space Environ Med; 1999 Sep; 70(9):867-73. PubMed ID: 10503751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we doing our best to educate travelers about the risks of acute mountain sickness? An on-site prospective study in the Himalayas.
    Paz A; Steinfeld I; Potasman I
    J Travel Med; 2007; 14(3):168-72. PubMed ID: 17437472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.